Willow GLP-1 Reviews vs PlexusDx (2026)

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

If you've been reading Willow GLP-1 reviews on Trustpilot, ConsumerAffairs, or Reddit, the picture is consistent: injectable patients tend to be satisfied, oral-tablet and sublingual-drop patients are noticeably less satisfied, and pricing starts at $299/month and climbs to $549/month for tirzepatide. Willow is a legitimate, LegitScript-certified telehealth provider dispensing compounded semaglutide and tirzepatide in 33 states. The question isn't whether Willow is real — it's whether Willow's pricing, formulary, and population-average titration approach is the right fit for you, or whether PlexusDx Semaglutide Injection, Tirzepatide Injection, or Microdose GLP-1 Protocol — available in all 50 states and pairable with the Precision Peptide Genetic Test — is a better match. This review walks the actual cost math, the compounded vs FDA-approved distinction, the patterns inside Willow's reviews, and where PlexusDx fits if you want a genetic baseline before week one.

Willow GLP-1 reviews — the short verdict

Across 300+ Trustpilot reviews and additional ConsumerAffairs and Reddit threads, three patterns repeat. First, injectable users (compounded semaglutide and especially compounded tirzepatide) report the strongest satisfaction and the most consistent weight-loss numbers. Second, oral semaglutide tablet and sublingual drop users post far more polarized reviews — some report results, many report none and switch to injectables. Third, customer service is described as responsive on the medical side and slower on the support-ticket side during high-volume periods. Pricing runs $299/month for compounded semaglutide (injection, tablet, or drops) and $399–$549/month for compounded tirzepatide. Willow is available in 33 states as of early 2026 and accepts HSA/FSA but not insurance. PlexusDx Weight Management Protocols span the same compounded-medication category at $129-$369/mo across six protocols, in all 50 states (5 require a live consult), with the optional Precision Peptide Genetic Test at $99 as an add-on after your first month so dosing decisions are tied to your GLP1R, GIPR, FTO, MC4R, and TCF7L2 variants rather than population averages.

What Willow actually dispenses — compounded, not FDA-approved branded

This is the substantive medication question and it matters before signing up anywhere. Willow prescribes compounded semaglutide and tirzepatide — pharmacy-prepared formulations of the same active ingredients found in Wegovy, Ozempic, Mounjaro, and Zepbound. Compounded semaglutide and tirzepatide are not FDA-approved finished drug products; only the branded versions (Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Rybelsus, Trulicity, Victoza) are FDA-approved. Willow's formulary covers compounded semaglutide injection, compounded semaglutide oral tablets, compounded semaglutide sublingual drops, compounded tirzepatide injection, and compounded tirzepatide sublingual drops. PlexusDx Weight Management Protocols also use compounded semaglutide and tirzepatide from licensed U.S. compounding pharmacies, with four delivery formats: weekly injection, daily oral, microdose troche/capsule/lozenge/sublingual, and dual-compound stacks via GLP-Squared. The compounded-vs-branded difference is about FDA approval status of the finished product, manufacturing oversight, and supply consistency — not about effectiveness of the active ingredient itself.

Willow vs PlexusDx pricing — the real annual cost

For a cash-pay patient, Willow's compounded semaglutide runs roughly $3,588/year ($299 × 12) on injection, oral tablet, or sublingual drops. Willow's compounded tirzepatide runs $4,788–$6,588/year ($399–$549 × 12). PlexusDx Weight Management Protocols compare as follows: Microdose GLP-1 Protocol at $129/mo flat ($1,548/year), Semaglutide Injection at $149/mo ($2,148–$2,748/year), Semaglutide Oral from $249/mo ($2,508/year+), Tirzepatide Injection at $249/mo ($2,748–$3,708/year), Tirzepatide Oral at $279/mo ($2,748–$6,108/year), and GLP-Squared dual-compound at $249/mo ($2,148–$3,900/year). On compounded semaglutide injection alone, PlexusDx is $840–$1,440/year less than Willow at the same medication category. On compounded tirzepatide injection, PlexusDx is roughly $2,040–$3,840/year less than Willow's tirzepatide pricing. Add the Precision Peptide Genetic Test at $99 as a one-time add-on after month one and the genetic-baseline-included totals still come in below Willow on the injection categories. Both providers are cash-pay with no insurance billing; PlexusDx adds no membership fee.

Willow oral tablets and drops — the needle-free reality check

The most consistent negative pattern inside Willow GLP-1 reviews concerns the oral semaglutide tablet and the sublingual drops. Reviewers report polarized outcomes: some patients see modest results, many see no measurable response and request a switch to injectables. The biological reason is straightforward — sublingual and buccal absorption of large peptide molecules like semaglutide is variable and generally lower than injection bioavailability. The FDA-approved oral semaglutide product (Rybelsus) achieves systemic absorption only with a specialized SNAC absorption-enhancer formulation taken on an empty stomach with strict water and timing rules; compounded oral and sublingual formats don't replicate that pharmacokinetic profile. If non-injection delivery is important to you, PlexusDx offers Semaglutide Oral across six dose levels (3mg–24mg daily) and the Microdose GLP-1 Protocol at $129/mo flat with four delivery variants (capsule, troche, lozenge, sublingual) for patients starting at lower doses or who want a needle-free entry point. Set realistic expectations either way: injection remains the most evidence-supported delivery format for both semaglutide and tirzepatide.

Safety, side effects, and the boxed warning

Willow's medications and PlexusDx protocols both prescribe in the GLP-1 receptor agonist class (semaglutide) or the GIP/GLP-1 dual-agonist class (tirzepatide). The labeled side-effect profile is the same across providers: nausea, vomiting, diarrhea, constipation, abdominal pain, and headache are common; pancreatitis, gallbladder disease, and acute kidney injury are documented but less common. The boxed warning for thyroid C-cell tumors applies to both semaglutide and tirzepatide based on rodent studies — relevant for anyone with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Compounded products carry additional uncertainty around manufacturing consistency relative to FDA-approved finished drugs; this applies equally to Willow's formulary and PlexusDx's compounded protocols. Both providers route through licensed U.S. compounding pharmacies with prescribing-clinician oversight; the structural difference is that PlexusDx pairs that oversight with an optional pharmacogenomic baseline through the Precision Peptide Genetic Test when individual variability is in question.

Where PlexusDx fits if you're cross-shopping Willow

Four scenarios separate Willow from PlexusDx cleanly. First, if you want compounded semaglutide injection at the lowest cash-pay price, PlexusDx Semaglutide Injection at $149/mo is below Willow's $299/mo flat. Second, if you want compounded tirzepatide injection at the lowest cash-pay price, PlexusDx Tirzepatide Injection at $249/mo is below Willow's $399–$549/mo. Third, if you live in one of the 17 states Willow doesn't yet cover, PlexusDx serves all 50 states (5 require a scheduled live consult). Fourth, if you want a measurable pharmacogenomic baseline before titration — not a population-average titration schedule with subjective tolerability adjustment over 8–12 weeks — the Precision Peptide Genetic Test ($298 standalone or $99 as an add-on after your first month) maps 48 genes, 57 variants, and 14 pathways including 34 weight-management insights and the GIPR rs1800437 variant linked to differential GLP-1 response. Neither Willow nor most telehealth GLP-1 providers include this step.

Frequently asked questions

Is Willow GLP-1 legit?

Yes. Willow is LegitScript-certified, prescribes through board-certified U.S. physicians, and dispenses through licensed compounding pharmacies. The medication category is compounded semaglutide and tirzepatide, which is not FDA-approved as a finished drug product. PlexusDx Weight Management Protocols operate in the same compounded-medication category with similar regulatory standing.

Is Willow cheaper than PlexusDx for compounded GLP-1?

No. Willow charges $299/mo for compounded semaglutide and $399–$549/mo for compounded tirzepatide. PlexusDx Semaglutide Injection runs $149/mo and Tirzepatide Injection runs $249/mo, with a $129/mo flat Microdose GLP-1 Protocol entry tier. PlexusDx is meaningfully less expensive at the same compounded medication category.

Do Willow oral tablets and sublingual drops actually work?

Reviews are polarized. Sublingual and buccal absorption of semaglutide is variable and generally lower than injection bioavailability. If a needle-free format matters to you, PlexusDx offers Semaglutide Oral and the Microdose GLP-1 Protocol with four delivery variants, but injection remains the most evidence-supported delivery format for weight loss.

Are Willow's GLP-1 medications FDA-approved?

No. Willow dispenses compounded semaglutide and tirzepatide, which are pharmacy-prepared and not FDA-approved as finished drug products. Only the branded versions — Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Rybelsus, Trulicity, and Victoza — are FDA-approved. PlexusDx's protocols use the same compounded-medication category from licensed U.S. compounding pharmacies.

Does Willow take insurance?

No. Willow is cash-pay only and accepts HSA/FSA payments. PlexusDx is also cash-pay with no insurance billing and no membership fee, available in all 50 states (5 require a scheduled live consult rather than async intake).

Why are Willow GLP-1 reviews so divided?

The split tracks medication format. Injectable reviewers are generally satisfied; oral tablet and sublingual drop reviewers are polarized. Customer service variability adds to the spread. If you want a measurable baseline rather than an empirical 8–12 week titration trial, the PlexusDx Precision Peptide Genetic Test ($99 add-on after month one) profiles 48 genes and 57 variants relevant to GLP-1 response.

What if I don't lose weight on a compounded GLP-1?

Give it 8–12 weeks at an appropriate dose with good adherence. If you're on an oral or sublingual format and not seeing results, consider switching to injection. If you're on injection and still not responding, your prescribing clinician may consider a switch from semaglutide to tirzepatide or a dual-compound approach like GLP-Squared. A pharmacogenomic profile can also clarify whether your GLP-1 response is biologically suboptimal versus a dosing or adherence issue.

Willow GLP-1 Reviews vs PlexusDx (2026): Honest Cost, Compounded Sourcing & Genetics Verdict | PlexusDx